This study demonstrates that if existing NMDA receptor antagonists are to be repurposed as an orally administered treatment for T2DM, it is essential that the effects of these drugs on the release of incretin hormones from the gut are fully investigated. The gene discussed is GCG; the disease is type 2 diabetes mellitus.